Immune checkpoint inhibitor-based immunotherapy targeting programmed cell with cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and death-ligand 1 (PD-L1) have shown significant efficacy against advanced cancer [11, 12]. The gene discussed is PDCD1; the disease is cancer.